Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) issued an update on its fourth quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $1.34-1.44 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.43. The company issued revenue guidance of $6.2-6.5 billion, compared to the consensus revenue estimate of $6.48 billion.Teva Pharmaceutical Industries also updated its FY16 guidance to $5.10-5.20 EPS.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) opened at 38.07 on Thursday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $37.25 and a 12 month high of $66.55. The company has a 50 day moving average of $42.97 and a 200-day moving average of $49.87. The firm has a market capitalization of $34.80 billion, a P/E ratio of 25.43 and a beta of 0.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The company had revenue of $5.56 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter last year, the business earned $1.35 earnings per share. Teva Pharmaceutical Industries’s revenue was up 15.3% on a year-over-year basis. Analysts predict that Teva Pharmaceutical Industries Ltd. will post $5.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Investors of record on Monday, December 5th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.57%. Teva Pharmaceutical Industries’s payout ratio is currently 58.39%.

TEVA has been the topic of a number of recent analyst reports. RBC Capital Markets restated an outperform rating and issued a $71.00 price target on shares of Teva Pharmaceutical Industries in a research report on Wednesday, July 20th. Mizuho restated a buy rating on shares of Teva Pharmaceutical Industries in a research report on Monday, July 25th. JPMorgan Chase & Co. reiterated an overweight rating and issued a $75.00 target price on shares of Teva Pharmaceutical Industries in a research report on Tuesday, July 26th. Vetr upgraded Teva Pharmaceutical Industries from a buy rating to a strong-buy rating and set a $60.02 target price on the stock in a research report on Monday, August 1st. Finally, Credit Suisse Group AG reiterated a neutral rating on shares of Teva Pharmaceutical Industries in a research report on Monday, August 1st. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries has an average rating of Buy and an average target price of $60.00.

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. WFG Advisors LP increased its position in shares of Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock worth $104,000 after buying an additional 256 shares during the period. Citizens Financial Group Inc RI increased its position in shares of Teva Pharmaceutical Industries by 17.1% in the second quarter. Citizens Financial Group Inc RI now owns 2,398 shares of the company’s stock worth $121,000 after buying an additional 351 shares during the period. Krilogy Financial LLC increased its position in shares of Teva Pharmaceutical Industries by 1.0% in the second quarter. Krilogy Financial LLC now owns 2,635 shares of the company’s stock worth $132,000 after buying an additional 25 shares during the period. SevenBridge Financial Group LLC acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter worth about $159,000. Finally, WESPAC Advisors SoCal LLC increased its position in shares of Teva Pharmaceutical Industries by 1.4% in the second quarter. WESPAC Advisors SoCal LLC now owns 3,550 shares of the company’s stock worth $178,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 63.00% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.